Company

Isomorphic Labs

AI-powered drug design company spun out from Alphabet/DeepMind, focused on applying AI across multiple therapeutic areas to accelerate drug discovery

Healthcare & Biotech

People

Demis Hassabisceo

Funding History

Apr 1, 2025

Isomorphic Labs raised $600M in its first external funding round to advance AI drug design across multiple therapeutic areas. The London-based company is a subsidiary of Alphabet and has existing partnerships with Eli Lilly and Novartis.

600M

Investors

Thrive CapitalGV

News

News (1)

Isomorphic Labs raises $600M in first external round to tackle AI drug design
31 Mar 2025